Skip to Content
Morningstar

Cronos Group Inc CRON

Morningstar Rating
Unlock
Stock XTSE Rating as of
CAD 3.30 −0.03 (0.90%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

First Pillar of Germany's Cannabis Legalization Begins April 1; Legal Sales to Come Later

Kristoffer Inton

The Bundestag, the lower house of Germany’s legislature, passed a cannabis bill last month that would allow possession of up to 25 grams and home-growing of up to three plants. The law will become effective April 1 as planned after the Bundesrat, the upper house, voted not to send it to mediation committee on March 22. The law expands on July 1 to allow nonprofit cannabis grow clubs of up to 500 members and 50 grams per member.

Read Full Report

Price vs Fair Value

View History
CRON is trading at a 18% premium.
Price
CAD 3.30
Fair Value
CAD 8.40
Uncertainty
Very High
1-Star Price
CAD 9.70
5-Star Price
CAD 6.70
Economic Moat
Mpkvv
Capital Allocation
Svpxnddwd

Bulls Say, Bears Say

Bulls

Altria Group’s investment of $1.8 billion provides Cronos with capital and a strategic partner with significant product development, branding, and regulatory experience. If successful, Altria Group may increase its ownership of Cronos or potentially acquire it.

Bears

Cronos' small size adds difficulty to reaching profitability, as it struggles to leverage overhead expenses.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRON is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
CAD 3.33
Day Range
CAD 3.28–3.38
52-Week Range
CAD 2.15–4.01
Bid/Ask
CAD 3.26 / CAD 3.39
Market Cap
CAD 1.26 Bil
Volume/Avg
185,806 / 228,278

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
10.67
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
356
Website
https://www.thecronosgroup.com

Competitors

Valuation

View More
Metric
CRON
TLRY
ACB
Price/Earnings (Normalized)
 ———
Price/Book Value
 0.860.400.80
Price/Sales
 10.671.651.16
Price/Cash Flow
 ———
Price/Earnings
CRON
TLRY
ACB

Financial Strength

Metric
CRON
TLRY
ACB
Quick Ratio
 21.680.891.79
Current Ratio
 22.541.633.79
Interest Coverage
 —−24.18—
Quick Ratio
CRON
TLRY
ACB

Profitability

Metric
CRON
TLRY
ACB
Return on Assets (Normalized)
 −0.53%−13.42%—
Return on Equity (Normalized)
 −0.55%−17.13%—
Return on Invested Capital (Normalized)
 −4.90%−14.23%—
Return on Assets
CRON
TLRY
ACB
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class AWpfkjtnnvMwrkw$70.0 Bil
MKKGY
Merck KGaA ADRCcqqmkwqxQfqhj$68.1 Bil
HLN
Haleon PLC ADRNvmmffpcLkrf$36.5 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRKvsgppxghDlmlm$14.3 Bil
VTRS
Viatris IncMxpskqlSjyz$13.2 Bil
RDY
Dr Reddy's Laboratories Ltd ADRZrwtwfdwLjfrb$12.0 Bil
CTLT
Catalent IncCywmlghrLnwwf$10.1 Bil
PRGO
Perrigo Co PLCQgcwlgbxVwl$4.1 Bil
CURLF
Curaleaf Holdings IncTgdqgdgmXsbpw$3.7 Bil
PBH
Prestige Consumer Healthcare IncThzhvqdfGtfjlvp$3.4 Bil

Sponsor Center